Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells

Liu,Xiangping; Wang,Jing; Wang,Haibo; Liu,Shihai; Liang,Ye; Lv,Zhidong; Zhou,Quan; Ding,Weili

doi:10.3892/or.2013.2653

Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells

Authors:
- Xiangping Liu
- Jing Wang
- Haibo Wang
- Shihai Liu
- Ye Liang
- Zhidong Lv
- Quan Zhou
- Weili Ding
View Affiliations

Affiliations: Central Laboratory of Molecular Biology, The Affiliated Hospital of the Medical College, Qingdao University, Qingdao 266003, P.R. China, Center of Diagnosis and Treatment of Breast Disease, The Affiliated Hospital of the Medical College, Qingdao University, Qingdao 266003, P.R. China
Published online on: August 2, 2013 https://doi.org/10.3892/or.2013.2653
Pages: 1913-1919

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand (TRAIL or Apo2L) is a member of the tumor necrosis factor superfamily that induces apoptosis in various cancer cell types but not in most normal cells. However, it is clear that not all cancer cells are sensitive to the killing effects of TRAIL, including breast cancer. Previous studies have demonstrated that chemotherapeutic drugs sensitize tumor cells to apoptosis induced by TRAIL in several types of malignancies. In the present study, we studied the effects of TRAIL combined with cisplatin on two breast cancer cell lines MDA-MB-468 and HCC-1937 in vitro. MTT assay, crystal violet staining assay, DAPI staining assay and flow cytometric analysis were undertaken to evaluate the enhancement of breast cancer cell death using Ad-sTRAIL and/or cisplatin. The levels of apoptotic molecules in signal transduction pathways were analyzed by real-time RT-PCR and western blotting. We found that co-treatment with Ad-sTRAIL and cisplatin exhibited stronger cytotoxicity and induced more significant apoptosis in breast cancer cells compared with Ad-sTRAIL or cisplatin alone. Pretreatment with cisplatin significantly enhanced the expression of DR5. Moreover, the induction of apoptosis by TRAIL plus cisplatin was accompanied by the downregulation of cFLIP and BCL2L1, and simultaneously robust enzymatic activation of caspase-8, culminating in decreased cancer cell survival. The present study revealed that TRAIL conjugated with cisplatin exhibited a markedly increased cytotoxic and apoptosis-inducing effect on breast cancer cells.

View Figures

View References

1	Curado MP: Breast cancer in the world: incidence and mortality. Salud Publica Mex. 53:372–384. 2011.PubMed/NCBI
2	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
3	Kelley SK and Ashkenazi A: Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol. 4:333–339. 2004. View Article : Google Scholar : PubMed/NCBI
4	Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
5	Ryo K, Kamogawa Y, Ikeda I, Yamauchi K, Yonehara S, Nagata S and Hayashi N: Significance of Fas antigen-mediated apoptosis in human fulminant hepatic failure. Am J Gastroenterol. 95:2047–2055. 2000. View Article : Google Scholar : PubMed/NCBI
6	Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, Song N, Teng Y and Liu Y: Down-regulation of Cbl-b by bufalin results in up-regulation of DR₄/DR₅ and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 138:1279–1289. 2012. View Article : Google Scholar : PubMed/NCBI
7	Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N and Brodeur GM: Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 61:1314–1319. 2001.
8	Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM and Reed JC: Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells. Cancer Res. 65:4799–4808. 2005. View Article : Google Scholar
9	Zhang L and Fang B: Mechanisms of resistance to TRAIL- inducing apoptosis in cancer. Cancer Gene Ther. 12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
10	Singh TR, Shankar S, Chen X, Asim M and Srivastava RK: Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res. 63:5390–5400. 2003.
11	Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ and Guillaudeux T: Sensitvity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Prostate. 66:987–995. 2006. View Article : Google Scholar : PubMed/NCBI
12	Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 22:7265–7279. 2003. View Article : Google Scholar : PubMed/NCBI
13	Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK and Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis inducing ligand in vitro and in vivo. Cancer Res. 60:847–853. 2000.
14	Boulikas T and Vougiouka M: Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs. Oncol Rep. 11:559–595. 2004.PubMed/NCBI
15	Burtness B, Goldwasser MA, Flood W, Mattar B and Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 23:8646–8654. 2005. View Article : Google Scholar : PubMed/NCBI
16	Wiezorek J, Holland P and Graves J: Death receptor agonists as a targeted therapy for cancer. J Clin Cancer Res. 16:1701–1708. 2010. View Article : Google Scholar : PubMed/NCBI
17	Mandel RJ, Manfredsson FP, Foust KD, Rising A, Reimsnider S, Nash K and Burger C: Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther. 13:463–483. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wagner JA, Reynolds T, Moran ML, Moss RB, Wine JJ, Flotte TR and Gardner P: Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet. 351:1702–1703. 1998. View Article : Google Scholar : PubMed/NCBI
19	Wang Y, Huang F, Cai H, Wu Y, He G and Tan W: The efficacy of combination therapy using adeno-associated virus-TRAIL targeting to telomerase activity and cisplatin in a mice model of hepatocellular carcinoma. J Clin Cancer Res. 136:1827–1837. 2010. View Article : Google Scholar
20	Kanazawa T, Urabe M, Mizukami H, Okada T, Kume A, Nishino H, Monahan J, Kitamura K, Ichimura K and Ozawa K: γ-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther. 8:99–106. 2001.
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C (T)) method. Methods. 25:402–408. 2001.
22	Lin J, Zhang Z, Zeng S, Zhou S, Liu BF, Liu Q, Yang J and Luo Q: TRAIL-induced apoptosis proceeding from caspase-3-dependent and independent pathways in distinct HeLa cells. Biochem Biophys Res Commun. 346:1136–1141. 2006. View Article : Google Scholar : PubMed/NCBI
23	Shankar S and Srivastava RK: Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist Updat. 7:139–156. 2004. View Article : Google Scholar : PubMed/NCBI
24	Shin EC, Seong YR, Kim CH, Kim H, Ahn YS, Kim K, Kim SJ, Hong SS and Park JH: Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp Mol Med. 34:114–122. 2002. View Article : Google Scholar : PubMed/NCBI
25	Jiang M, Liu Z, Xiang Y, Ma H, Liu S, Liu Y and Zheng D: Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer. 11:54–65. 2011. View Article : Google Scholar : PubMed/NCBI
26	Liping X, Shuping Y and Kaladhar BR: Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Mol Cancer Ther. 10:550–557. 2011. View Article : Google Scholar : PubMed/NCBI
27	Seol DW, Li J, Seol MH, Park SY, Talanian RV and Billiar TR: Signaling events triggered by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis. Cancer Res. 61:1138–1143. 2001.PubMed/NCBI
28	Brunetti G, Colucci S, Rizzi R, Mori G, Colaianni G, Oranger A, Zallone A, Liso V and Grano M: The role of OPG/TRA IL complex in multiple meloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple meloma-bone disease. Ann NY Acad Sci. 1068:334–340. 2006. View Article : Google Scholar : PubMed/NCBI
29	Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818–821. 1997. View Article : Google Scholar : PubMed/NCBI
30	Fulda S, Meyer E and Debatin KM: Inhibition of TRAIL-induced apoptosis by BCL2 overexpression. Oncogene. 21:2283–2294. 2002. View Article : Google Scholar : PubMed/NCBI
31	Van Geelen CM, de Vries EG and de Jong S: Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat. 7:345–358. 2004.PubMed/NCBI
32	Vander Heiden MG, Chandel NS, Williamson EK, Schumacker PT and Thompson CB: Bcl-Xl regulates the membrane potential and volume homeostasis of mitochondria. Cell. 91:627–637. 1997.PubMed/NCBI
33	Harris MH and Thompson CB: The role of the BCL2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 7:1182–1191. 2000. View Article : Google Scholar : PubMed/NCBI
34	Kim IK and Jung YK, Noh DY, Song YS, Choi CH, Oh BH, Masuda ES and Jung YK: Functional screening of genes suppressing TRAIL-induced apoptosis: distinct inhibitory activities of Bcl-X_L and Bcl-2. Br J Cancer. 88:910–917. 2003. View Article : Google Scholar : PubMed/NCBI
35	Lee TJ, Lee JT, Park JW and Kwon TK: Acquired TRAIL resistance in human breast cancer cells are caused by the sustained cFLIP(L) and XIAP protein levels and ERK activation. Biochem Biophys Res Commun. 351:1024–1030. 2006. View Article : Google Scholar : PubMed/NCBI
36	Bellail AC, Tse MC, Song JH, Phuphanich S, Olson JJ, Sun SY and Hao C: DR5-mediated DISC controls caspase-8 cleavage and initiation of apoptosis in human glioblastomas. J Cell Mol Med. 14:1303–1317. 2010. View Article : Google Scholar : PubMed/NCBI
37	Wang P, Zhang J, Anita B, Jiang W, Judith H, Norman MK and Hao C: Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells. Cell Signal. 19:2237–2246. 2007. View Article : Google Scholar : PubMed/NCBI
38	Brooks AD and Sayers TJ: Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis. Cancer Immunol Immunother. 54:499–505. 2005. View Article : Google Scholar : PubMed/NCBI